AbCellera Biologics Balance Sheet
NASDAQ: ABCLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
AbCellera Biologics financial position
At the end of fiscal 2025, AbCellera Biologics reported total assets of $1.36 billion, down 0.3% from a year earlier against total liabilities of $390.0 million. Shareholders' equity stood at $966.9 million, or 71.3% of assets. The company held $128.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 11.32, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
AbCellera Biologics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 128.51M | 156.32M | 133.32M | 386.54M | 476.14M | 594.12M | — |
| Receivables | 39.41M | 31.98M | 0 | — | — | 903.00K | — |
| Inventory | 6.34M | 0 | — | — | — | — | — |
| Total Current Assets | 728.23M | 751.37M | 871.99M | 1.03B | 929.80M | 813.33M | — |
| Property, Plant & Equipment | — | — | — | 217.25M | 111.62M | 17.92M | — |
| Goodwill | 47.81M | 47.81M | 47.81M | 47.81M | 47.81M | 31.50M | — |
| Intangible Assets | 38.38M | 42.11M | 120.42M | 131.50M | 148.39M | 115.15M | 0 |
| Total Assets | 1.36B | 1.36B | 1.49B | 1.54B | 1.32B | 1.01B | — |
| Accounts Payable | 25.23M | 34.35M | 28.60M | 14.83M | 14.92M | 7.32M | — |
| Short-Term Debt | — | — | — | — | — | 190.00K | — |
| Total Current Liabilities | 64.31M | 76.61M | 119.01M | 118.32M | 120.68M | 103.49M | — |
| Total Liabilities | 390.05M | 304.47M | 335.78M | 307.63M | 292.84M | 175.03M | — |
| Shareholders' Equity | 966.90M | 1.06B | 1.15B | 1.23B | 1.03B | 830.51M | 10.25M |
| Retained Earnings | -29.48M | 116.93M | 279.79M | 426.19M | 267.67M | 114.20M | — |
| Total Debt | — | — | — | — | — | 190.00K | — |
| Net Cash (Debt) | 128.51M | 156.32M | 133.32M | 386.54M | 476.14M | 593.93M | — |
| Shares Outstanding | 300.60M | 295.76M | 290.82M | 286.85M | 283.26M | 269.50M | — |
This table shows 7 annual periods of AbCellera Biologics's balance sheet, from FY 2025 back to FY 2019, across 17 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow ABCL's reporting calendar. What is a balance sheet?